Cargando…
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention. However, there are considerable issues regarding statin safety and further development of residual risk control...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100224/ https://www.ncbi.nlm.nih.gov/pubmed/21625418 http://dx.doi.org/10.2147/DDDT.S13492 |
_version_ | 1782204163168403456 |
---|---|
author | Kawai, Yasuyuki Sato-Ishida, Ryoko Motoyama, Atsushi Kajinami, Kouji |
author_facet | Kawai, Yasuyuki Sato-Ishida, Ryoko Motoyama, Atsushi Kajinami, Kouji |
author_sort | Kawai, Yasuyuki |
collection | PubMed |
description | Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention. However, there are considerable issues regarding statin safety and further development of residual risk control, particularly for diabetic and metabolic syndrome patients. Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects comparable to those of atorvastatin or rosuvastatin. Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism. Considering these factors along with its unique pharmacokinetic properties, which suggest minimal drug–drug interaction, pitavastatin could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus. Many clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings and are expected to provide further information. |
format | Text |
id | pubmed-3100224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31002242011-05-27 Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus Kawai, Yasuyuki Sato-Ishida, Ryoko Motoyama, Atsushi Kajinami, Kouji Drug Des Devel Ther Review Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention. However, there are considerable issues regarding statin safety and further development of residual risk control, particularly for diabetic and metabolic syndrome patients. Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects comparable to those of atorvastatin or rosuvastatin. Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism. Considering these factors along with its unique pharmacokinetic properties, which suggest minimal drug–drug interaction, pitavastatin could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus. Many clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings and are expected to provide further information. Dove Medical Press 2011-05-11 /pmc/articles/PMC3100224/ /pubmed/21625418 http://dx.doi.org/10.2147/DDDT.S13492 Text en © 2011 Kawai et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Kawai, Yasuyuki Sato-Ishida, Ryoko Motoyama, Atsushi Kajinami, Kouji Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title_full | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title_fullStr | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title_full_unstemmed | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title_short | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
title_sort | place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100224/ https://www.ncbi.nlm.nih.gov/pubmed/21625418 http://dx.doi.org/10.2147/DDDT.S13492 |
work_keys_str_mv | AT kawaiyasuyuki placeofpitavastatininthestatinarmamentariumpromisingevidenceforaroleindiabetesmellitus AT satoishidaryoko placeofpitavastatininthestatinarmamentariumpromisingevidenceforaroleindiabetesmellitus AT motoyamaatsushi placeofpitavastatininthestatinarmamentariumpromisingevidenceforaroleindiabetesmellitus AT kajinamikouji placeofpitavastatininthestatinarmamentariumpromisingevidenceforaroleindiabetesmellitus |